RU2001118855A - ANALOGUES GLP-1 - Google Patents

Claims (18)

1. The compound of formula (I) (R ² R ³ ) -A ⁷ -A ⁸ -A ⁹ -A ^l0 -A ¹¹ -A ¹² -A ^l3 -A ¹⁴ -A ¹⁵ -A ¹⁶ -A ¹⁷ -A ¹⁸ - A ¹⁹ -A ²⁰ -A ²¹ -A ²² -A ²³ -A ²⁴ -A ²⁵ -A ²⁶ -A ²⁷ -A ²⁸ -A ²⁹ -A ³⁰ -A ³¹ -A ³² -A ³³ -A ³⁴ -A ³⁵ -A ³⁶ -A ³⁷ -A ³⁸ -A ³⁹ - R ¹ , (I) where A ⁷ represents L-His, Ura, Paa, Pta, Amp, Tma-His, desamino-His, or deleted; A ⁸ is —Ala, D-Ala, Aib, Ace, N-Me-Ala, N-Me-D-Ala or N-Me-Gly; A ⁹ represents Glu, N-Me-Glu, N-Me-Asp or Asp; A ¹⁰ represents Gly, Acc, β-Ala or Aib; A ¹¹ represents Thr or Ser; A ¹² is Phe, Acc, Aic, Aib, 3-Pal, 4-Pal, β-Nal, Cha, Trp or X ¹ -Phe; A ¹³ represents Thr or Ser; A ¹⁴ represents Ser or Aib; A ¹⁵ represents Asp or Glu; A ¹⁶ represents Val, Acc, Aib, Leu, Ile, Tle, Nle, Abu, Ala or Cha; A ¹⁷ represents Ser or Thr; A ¹⁸ is Ser or Thr; And ¹⁹ represents Tyr, Cha, Phe, 3-Pal, 4-Pal, Acc, β-Nal or X ¹ -Phe; And ²⁰ represents Leu, Acc, Aib, Nle, Ile, Cha, Tle, Val, Phe or X ¹ -Phe; A ²¹ represents Glu or Asp; A ²² is Gly, Acc, β-A1a, Glu or Aib; A ²³ represents Gln, Asp, Asn or Glu; A ²⁴ represents Ala, Aib, Val, Abu, Tle or Acc; A ²⁵ represents Ala, Aib, Val, Abu, Tle, Acc, Lys, Arg, hArg, Orn, HN-CH ((CH ₂ ) _n -N (R ¹⁰ R ¹¹ )) - C (O) or HN- CH ((CH ₂ ) _e -X ³ ) -C (O); And ²⁶ represents Lys, Arg, hArg, Orn, HN-CH ((CH ₂ ) _n -N (R ¹⁰ R ¹¹ )) - C (O) or HN-CH ((CH ₂ ) e-X ³ ) - C (O); A ²⁷ represents Glu, Asp, Leu, Aib or Lys; A ²⁸ is Phe, Pal, β-Nal, X ¹ -Phe, Aic, Acc, Aib, Cha or Trp; A ²⁹ represents Ile, Acc, Aib, Leu, Nle, Cha, Tle, Val, Abu, Ala or Phe; A ³⁰ is Ala, Aib or Acc; A ³¹ is Trp, β-Nal, 3-Pal, 4-Pal, Phe, Acc, Aib or Cha; A ³² is Leu, Acc, Aib, Nle, Ile, Cha, Tle, Phe, X ¹ -Phe or Ala; A ³³ is Val, Acc, Aib, Leu, Ile, Tle, Nle, Cha, Ala, Phe, Abu, Lys or X ¹ -Phe; A ³⁴ represents Lys, Arg, hArg, Orn, HN-CH ((CH ₂ ) _n -N (R ¹⁰ R ¹¹ )) - C (O) or HN-CH ((CH ₂ ) _e -X ³ ) - C (O); A ³⁵ is Gly, β-Ala, D-Ala, Gaba, Ava, HN- (CH ₂ ) _m -C (O), Aib, Acc or D-amino acid; A ³⁶ is L- or D-Arg, D- or L-Lys, D- or L-hArg, D- or L-Orn, HN-CH ((CH ₂ ) _n -N (R ¹⁰ R ¹¹ )) —C (O), HN — CH ((CH ₂ ) _e —X ³ ) —C (O), or deleted; A ³⁷ is Gly, β-Ala, Gaba, Ava, Aib, Ace, Ado, Arg, Asp, Aun, Aec, HN- (CH ₂ ) _m -C (O), HN-CH ((CH ₂ ) _n -N (R ¹⁰ R ¹¹ ) -C (O), D-amino acid, or deleted; A ³⁸ is D- or L-Lys, D- or L-Arg, D- or L-hArg, D- or L-Orn, HN-CH ((CH ₂ ) _n -N (R ¹⁰ R ¹¹ )) —C (O), HN — CH ((CH ₂ ) _e —X ³ ) —C (O) Ava, Ado, Aec, or deleted; A ³⁹ is D- or L-Lys, D- or L-Arg, HN-CH ((CH ₂ ) _n -N (R ¹⁰ R ¹¹ )) - C (O), Ava, Ado, or Aec; X ¹ in each case is independently selected from the group consisting of (C ₁ -C ₆ ) alkyl, OH and halogen; R ¹ represents OH, NH ₂ , (C ₁ -C ₃₀ ) alkoxy, or NH-X ² -CH ₂ -Z ⁰ , where X ² represents a (C ₁ -C ₁₂ ) hydrocarbon fragment, and Z ⁰ represents H, OH, CO ₂ H or CONH ₂ ;

X ³ represents

or —C (O) —NHR ¹² , where X ⁴ represents, in each case independently, —C (O) -, —NH — C (O) -, or —CH ₂ -; f is, in each case, independently, an integer from 1 to 29 inclusive; each of R ² and R ^{3 is} independently selected from the group consisting of H, (C ₁ -C ₃₀ ) alkyl, (C ₂ -C ₃₀ ) alkenyl, phenyl (C ₁ -C ₃₀ ) alkyl, naphthyl (C ₁ -C ₃₀ ) alkyl, hydroxy (C ₁ -C ₃₀ ) alkyl, hydroxy (C ₂ -C ₃₀ ) alkenyl, hydroxyphenyl (C ₁ -C ₃₀ ) alkyl, and hydroxy-naphthyl (C ₁ -C ₃₀ ) alkyl; or one of R ² and R ³ represents

(C ₁ -C ₃₀ ) acyl, (C ₁ -C ₃₀ ) alkylsulfonyl, C (O) X ⁵ ,

or

where Y represents H, OH or NH ₂ ; r is 0-4; q is 0-4; X ⁵ represents (C ₁ -C ₃₀ ) alkyl, (C ₂ -C ₃₀ ) alkenyl, phenyl (C ₁ -C ₃₀ ) alkyl, naphthyl (C ₁ -C ₃₀ ) alkyl, hydroxy (C ₁ -C ₃₀ ) alkyl, hydroxy (C ₂ -C ₃₀ ) alkenyl, hydroxyphenyl (C ₁ -C ₃₀ ) alkyl or hydroxy-naphthyl (C ₁ -C ₃₀ ) alkyl; e is, in each case, independently, an integer from 1 to 4 inclusive; m is, in each case, independently, an integer from 5 to 24 inclusive; n represents, in each case, independently, an integer from 1 to 5 inclusive; each of R ¹⁰ and R ¹¹ is, in each case, independently H, (C ₁ -C ₃₀ ) alkyl, (C ₁ -C ₃₀ ) acyl, (C ₁ -C ₃₀ ) alkylsulfonyl, -C ((NH) (NH ₂ )) or

R ¹² and R ¹³ each represents, in each case independently, (C ₁ -C ₃₀ ) alkyl; provided that if A ⁷ is Ura, Paa or Pta, then R ² and R ^{3 are} removed; if R ¹⁰ is (C ₁ -C ₃₀ ) acyl, (C ₁ -C ₃₀ ) alkylsulfonyl, —C ((NH) (NH ₂ )), or

then R ¹¹ represents H or (C ₁ -C ₃₀ ) alkyl; (i) at least one amino acid of the compound of formula (I) is different from the corresponding amino acid of the native sequence hGLP-1 (7-36, -37 or -38) NH ₂ or hGLP-1 (7-36, -37 or -38) HE; (ii) the compound of formula (I) is not an analogue of hGLP-1 (7-36, -37 or -38) NH ₂ or hGLP-1 (7-36, -37 or -38) OH, where the substitution is made in a single position on Ala; (iii) the compound of formula (I) is not (Arg ^26.34 , Lys ³⁸ ) hGLP-1 (7-38) -E, (Lys ²⁶ (Nε-alkanoyl)) hGLP-1 (7-36, -37 or -38) -E, (Lys ³⁴ (Nε-alkanoyl)) hGLP-1 (7-36, -37 or -38) -E, (Lys ^26.34- bis (Nε-alkanoyl)) hGLP-1 (7 -36, -37 or -38) -E, (Arg ²⁶ , Lys ³⁴ (Nε-alkanoyl)) hGLP-1 (8-36, -37 or -38) -E, (Arg ^26.34 , Lys ³⁶ ( Nε-alkanoyl)) hGLP-1 (7-36, -37 or -38) -E or (Arg ^26.34 , Lys ³⁸ (Nε-alkanoyl)) hGLP-1 (7-38) -E, where E represents is —OH or —NH ₂ ; (iv) the compound of formula (I) is not Z ^1- hGLP-1 (7-36, -37 or -38) -OH, Z ¹ -hGLP-1 (7-36, -37 or -38) -NH ₂ where Z ^{1 is} selected from the group consisting of: (e) (Arg ²⁶ ), (Arg ³⁴ ), (Arg ^26.34 ), (Lys ³⁶ ), (Arg ²⁶ , Lys ³⁶ ), (Arg ³⁴ , Lys ³⁶ ), (D-Lys ³⁶ ), (Arg ³⁶ ), (D-Arg ³⁶ ), (Arg ^26.34 , Lys ³⁶ ) or (Arg ^26.36 , Lys ³⁴ ); (f) (Asp ²¹ ); (g) at least one of (Aib ⁸ ), (D-Ala ⁸ ) and (Asp ⁹ ); and (h) (Tyr ⁷ ), (N-acyl-His ⁷ ), (N-alkyl-His ⁷ ), (N-acyl-D-His ⁷ ) or (N-alkyl-D-His ⁷ ); (v) the compound of formula (I) is not a combination of any two substitutions listed in groups (a) to (d); and (vi) the compound of formula (I) is not (N-Me-Ala ⁸ ) hGLP-1 (8-36, or -37), (Glu ¹⁵ ) hGLP-1 (7-36, or -37), ( Asp ²¹ ) hGLP-1 (7-36, or -37) or (Phe ³¹ ) hGLP-1 (7-36, or -37), or a pharmaceutically acceptable salt thereof. 2. The compound according to claim 1, where A ¹¹ represents Thr; A ¹³ is Thr; A ¹⁵ represents Asp; A ¹⁷ represents Ser; A ¹⁸ is Ser; A ²¹ represents Glu; A ²³ represents Gln or Glu; A ²⁷ represents Glu; and A ³¹ represents Trp; or a pharmaceutically acceptable salt thereof. 3. The compound according to claim 2, where A ⁹ represents Glu, N-Me-Glu or N-Me-Asp; A ¹² represents Phe, Acc or Aic; A ¹⁶ represents Val, Acc or Aib; A ¹⁹ is Tyr; And ²⁰ represents Leu, Acc or Cha; A ²⁴ represents Ala, Aib or Acc; A ²⁵ represents Ala, Aib, Acc, Lys, Arg, hArg, Orn, HN-CH ((CH ₂ ) _n -N (R ¹⁰ R ¹¹ )) - C (O) or HN-CH ((CH ₂ ) _e- X ³ ) -C (O); A ²⁸ represents Phe; A ²⁹ represents Ile or Acc; A ³⁰ is Ala or Aib; A ³² represents Leu, Acc or Cha; and A ³³ represents Val or Acc; or a pharmaceutically acceptable salt thereof. 4. The compound according to claim 3, where A ⁸ represents Ala, D-Ala, Aib, A6c, A5c, N-Me-Ala, N-Me-D-Ala or N-Me-Gly; A ¹⁰ represents Gly; A ¹² is Phe, A6c or A5c; A ¹⁶ represents Val, A6c or A5c; A ²⁰ is Leu, A6c, A5c or Cha; A ²² represents Gly, β-Ala or Aib; A ²⁴ represents Ala or Aib; A ²⁹ represents Ile, A6c or A5c; A ³² is Leu, A6c, A5c or Cha; A ³³ is Val, A6c or A5c; A ³⁵ is Aib, β-Ala, Ado, A6c, A5c or Gly; and A ³⁷ is Gly, Aib, β-Ala, Ado, D-Ala or is deleted; or a pharmaceutically acceptable salt thereof. 5. The compound according to claim 4 or a pharmaceutically acceptable salt thereof, wherein X ⁴ in each case is —C (O) -; e in each case independently represents 1 or 2; and R ¹ represents OH or NH ₂ . 6. The compound according to claim 5 or a pharmaceutically acceptable salt thereof, wherein R ² is H and R ³ is (C ₁ -C ₃₀ ) alkyl, (C ₂ -C ₃₀ ) alkenyl, (C ₁ -C ₃₀ ) acyl , (C ₁ -C ₃₀ ) alkylsulfonyl,

or

7. The compound according to claim 5 or its pharmaceutically acceptable salt, where R ¹⁰ represents (C ₁ -C ₃₀ ) acyl, (C ₁ -C ₃₀ ) alkylsulfonyl or

and R ¹¹ represents N. 8. The compound according to claim 7 or its pharmaceutically acceptable salt, where R ¹⁰ represents (C ₄ -C ₂₀ ) acyl, (C ₄ -C ₂₀ ) alkylsulfonyl or

9. The compound of claim 1, wherein said compound is (Aib ^8.35 ) hGLP-1 (7-36) NH ₂ , ((Nα-HEPES-His) ⁷ , Aib ^8.35 ) hGLP-1 (7-36) NH ₂ , ((Nα-HEPA-His) ⁷ , Aib ^8.35 ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁶ (Nε-tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , Lys ³⁴ (Nε-tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35.37 , Arg ^26.34 , Lys ³⁸ (Nε-tetradecanoyl)) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁶ (Nε-decanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁶ (Nε-dodecansulfonyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys36 (Nε- (2- (4-tetradecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Asp ³⁶ (1- (4-tetradecyl-piperazine)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁶ (1-tetradecylamino)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys36 (Nε-tetradecanoyl), β- Ala ³⁷ ) hGLP-1 (7-37) -OH, or (Aib ^8.35 , Arg ^26.34 , Lys ³⁶ (Nε-tetradecanoyl)) hGLP-1 (7-36) -OH,  or a pharmaceutically acceptable salt thereof. 10. The compound of claim 9, wherein said compound is (Aib ^8.35 ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , Lys ³⁴ (Nε-tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35.37 , Arg ^26.34 , Lys ^{38 (} Nε-tetradecanoyl)) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁶ (Nε-decanoyl)) hGLP-1 (7-36) NH ₂ , or (Aib ^8.35 , Arg ^26.34 , Lys ³⁶ (Nε-tetradecanoyl), β-Ala ³⁷ ) hGLP-1 (7-37) -OH, or a pharmaceutically acceptable salt thereof. 11. A pharmaceutical composition comprising an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. 12. A method of inducing an agonistic effect on a GLP-1 receptor in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof. 13. A method of treating a disease selected from the group consisting of type I diabetes, type II diabetes, obesity, glucagonomas, secretory disorders of the respiratory tract, metabolic disorders, arthritis, osteoporosis, diseases of the central nervous system, restenosis and neurodegenerative diseases in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof. 14. The method of claim 13, wherein said disease is type I diabetes or type II diabetes. 15. The method according to claim 1, where the said compound is a (Aib ³⁵ ) hGLP-1 (7-36) NH ₂ , (β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , ((Nα-Me-His) ⁷ , Aib ^8.35 ) hGLP-1 (7-36) NH ₂ , ((Nα-Me-His) ⁷ , Aib ⁸ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , ((Nα-Me-His) ⁷ , Aib ^8.35 , Arg ^26.34 ) hGLP-1 (7-36) NH ₂ , ((Nα-Me-His) ⁷ , Aib ⁸ , Arg ^26.34 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , A6c ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , A5c ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , D-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , A6c ³² ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , A5c ³² ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.35 ) hGLP-1 (7-36) NH ₂ , (Aib ^8.30.30 ) hGLP-1 (7-36) NH ₂ , (Aib ^8.25.35 ) hGLP-1 (7-36) NH ² , (Aib ^8.35 , A6c ^16.20 ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , A6c ^16.29.29.32 ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , A6c ^20.32 ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , A6c ²⁰ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ²⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.35 , A6c ²⁰ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , A6c ^29.32 ) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.35 , A6c ^29.32 ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , A6c ¹² ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Cha ²⁰ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , A6c ³³ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , A6c ^20.32 ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , A6c ^16.20 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , β-Ala ²² ) hGLP-1 (7-36) NH ₂ , (Aib ^8.22.35 ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , A6c ³² ) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.35 , Glu ²³ , A6c ³² ) hGLP-1 (7-36) NH ₂ , (Aib ^8,24,25,35 , Glu ²³ , A6c ³² ) hGLP-1 (7-36) NH ₂ , (Aib ^8.24 , ^.25.35 , A6c ^16.20.32 , Glu ²³ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , A6c ³² , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , A5c ³² , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Glu ²³ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.24 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.30 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.25 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , A6c ^16.20 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , A6c ^16,29,32 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , A6c ^20.32 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , A6c ²⁰ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ²⁵ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.24 , A6c ²⁰ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , A6c ^29.32 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.24 , A6c ^29.32 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , A6c ¹² , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Cha ²⁰ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , A6c ³³ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , A6c ^20.32 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.22 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Glu ²³ , A6c ³² , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.24 , Glu ²³ , A6c ³² , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.24 , Glu ²³ , A6c ³² , Lys ³⁴ (N _ε- octanoyl), β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.25 , Glu ²³ , A6c ³² , β- ^Ala35 ) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.25 , A6c ^16.20.32 , Glu ²³ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , D-Arg ³⁶ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , D-Lys ³⁶ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , β-Ala ³⁵ , D-Arg ³⁶ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , β-Ala ³⁵ , D-Lys ³⁶ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ^26.34 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26.34 ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26.34 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ^26.34 , β-Ala ³⁵ , Lys ³⁵ (Nε-tetradecanoyl)) hGLP-1 (7-36) OH, (Aib ^8.35 , Arg ^26.34 , Lys ³⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-37) OH, (Aib ^8.35.37 , Arg ^26.34 , Lys ³⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-37) OH, (Aib ^8.35 , Arg ^26.34 , Lys ³⁶ (N ^ε -tetradecanoyl), D-Ala ³⁷ ) hGLP-1 (7-37) OH, (Aib ^8.35.37 , Arg ^26.34 , Lys ³⁸ (N ^ε -tetradecanoyl)) hGLP-1 (7-38) OH, (Aib ^8.35 , Arg ^26.34 , β-Ala ³⁷ , Lys ³⁸ (N ^ε -tetradecanoyl)) hGLP-1 (7-38) OH, (Aib ^8.35 , Arg ^26.34 , Lys ³⁸ (N ^ε -tetradecanoyl)) hGLP-1 (7-38) OH, (Aib ⁸ , Arg ^26.34 , Lys ³⁶ (N ^ε -tetradecanoyl), β-Ala ³⁷ ) hGLP-1 (7-37) OH, (Aib ^8.37 , Arg ^26.34 , Lys ³⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-37) OH, (Aib ^8.35 , Arg ^26.34 , Ado ³⁷ ) hGLP-1 (7-37) OH, (Aib ^8.35 , Arg ^26.34 , Ado ³⁷ ) hGLP-1 (7-37) NH ₂ , (Aib ⁸ , Arg ^26.34 , Lys ³⁶ (N ^ε -tetradecanoyl), D-Ala ³⁷ ) hGLP-1 (7-37) OH, (Aib ^8.37 , Arg ^26.34 , Lys ³⁸ (N ^ε -tetradecanoyl)) hGLP-1 (7-38) OH, (Aib ⁸ , Arg ^26.34 , β-Ala ³⁷ , Lys ³⁸ (N ^ε -tetradecanoyl)) hGLP-1 (7-38) OH, (Aib ^8.35 , Lys ²⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ²⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ²⁶ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ²⁶ (N ^ε- octanoyl), β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ²⁶ (N ^ε -tetradecanoyl), β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ²⁶ (N ^ε- hexadecanoyl), β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ²⁶ (N ^ε- octanoyl), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ²⁶ (N ^ε -tetradecanoyl), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ²⁶ (N ^{ε ε-} hexadecanoyl), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ²⁶ (N ^ε- decanoyl), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ²⁵ , Lys ²⁶ (N ^ε- octanoyl), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ²⁵ , Lys ²⁶ (N ^ε -tetradecanoyl), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ²⁵ , Lys ²⁶ (N ^ε- hexadecanoyl), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.34 , Lys ²⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.34 , Lys ²⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.34 , Lys ²⁶ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.34 , Lys ²⁶ (N ^ε -decanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ²⁶ (N ^ε- octanoyl), Arg ³⁴ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ²⁶ (N ^ε -tetradecanoyl), Arg ³⁴ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ²⁶ (N ^ε- hexadecanoyl), Arg ³⁴ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ²⁶ (N ^ε- decanoyl), Arg ³⁴ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ³⁴ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ³⁴ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ³⁴ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , Lys ³⁴ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , Lys ³⁴ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , Lys ³⁴ (N ^ε -decanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26 , Lys ³⁴ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26 , Lys ³⁴ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26 , Lys ³⁴ (N ^ε -hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26 , Lys ³⁴ (N ^ε -decanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ²⁵ , Arg ²⁶ , Lys ³⁴ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ²⁵ , Arg ²⁶ , Lys ³⁴ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ²⁵ , Arg ²⁶ , Lys ³⁴ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ³⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ³⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ³⁶ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , Lys ³⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , Lys ³⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , Lys ³⁶ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁶ (N ^ε- hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁸ (N ^ε- octanoyl)) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁸ (N ^ε -decanoyl)) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁸ (N ^ε -tetradecanoyl)) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁸ (N ^ε- hexadecanoyl)) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^25.26.34 , Lys ³⁸ (N ^ε- octanoyl)) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^25.26.34 , Lys ³⁸ (N ^ε- decanoyl)) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^25.26.34 , Lys ³⁸ (N ^ε -tetradecanoyl)) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^25.26.34 , Lys ³⁸ (N ^ε -hexadecanoyl)) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^26.34 , Lys ³⁸ (N ^ε- octanoyl)) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^26.34 , Lys ³⁸ (N ^ε -decanoyl)) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^26.34 , Lys ³⁸ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^25.26.34 , Lys ³⁸ (N ^ε- octanoyl)) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^25.26.34 , Lys ³⁸ (N ^ε- decanoyl)) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^25.26.34 , Lys ³⁸ (N ^ε -tetradecanoyl)) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^25.26.34 , Lys ³⁸ (N ^ε -hexadecanoyl)) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Lys ²⁵ , Arg ^26.34 , Lys ³⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ²⁵ , Arg ^26.34 , Lys ³⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ²⁵ , Arg ^26.34 , Lys ³⁶ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26.34 , Lys ³⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26.34 , Lys ³⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26.34 , Lys ³⁶ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26.34 , Lys ³⁶ (N ^ε -decanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ³⁴ (N ^ε- octanoyl), β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , A6c ³² , Lys ³⁴ (N ^ε -tetradecanoyl), β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ³⁴ (N ^ε- hexadecanoyl), β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ³⁴ (N ^ε- octanoyl), β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Glu ²³ , Lys ³⁴ (N ^ε- octanoyl), β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Glu ²³ , A6c ³² , Lys ³⁴ (N ^ε- octanoyl), β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ²⁶ , Lys ³⁴ (N ^ε- octanoyl), β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ²⁶ , Lys ³⁴ (N ^ε -tetradecanoyl), β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ²⁶ , Lys ³⁴ (N ^ε- hexadecanoyl), β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ²⁶ , Lys ³⁴ (N ^ε- decanoyl), β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ^25.26 , Lys ³⁴ (N ^ε- octanoyl), β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ^25.26 , Lys ³⁴ (N ^ε -tetradecanoyl), β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ^25.26 , Lys ³⁴ (N ^ε -hexadecanoyl), β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ^25.26 , Lys ³⁴ (N ^ε- decanoyl), β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ²⁵ , Arg ²⁶ , Lys ³⁴ (N ^ε- octanoyl), β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ²⁵ , Arg ²⁶ , Lys ³⁴ (N ^ε -tetradecanoyl), β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ²⁵ , Arg ²⁶ , Lys ³⁴ (N ^{ε ε-} hexadecanoyl), β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , β-Ala ³⁵ , Lys ³⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , β-Ala ³⁵ , Lys ³⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , β-Ala ³⁵ , Lys ³⁶ (N ^ε -hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ²⁶ , β-Ala ³⁵ , Lys ³⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ²⁶ , β-Ala ³⁵ , Lys ³⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ²⁶ , β-Ala ³⁵ , Lys ³⁶ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ^26.34 , β-Ala ³⁵ , Lys ³⁶ (N ^{ε ε-} octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ^26.34 , β-Ala ³⁵ , Lys ³⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ^26.34 , β-Ala ³⁵ , Lys ³⁶ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ^26.34 , β-Ala ³⁵ , Lys ³⁶ (N ^ε- decanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ²⁵ , Arg ^26.34 , β-Ala ³⁵ , Lys ³⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ²⁵ , Arg ^26.34 , Lys ³⁶ (N ^ε -tetradecanoyl) β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ²⁵ , Arg ^26.34 , β-Ala ³⁵ , Lys ³⁶ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ^25.26.34 , β-Ala ³⁵ , Lys ³⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ^25.26.34 , β-Ala ³⁵ , Lys ³⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ^25.26.34 , β-Ala ³⁵ , Lys ³⁶ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ^25.26.34 , β-Ala ³⁵ , Lys ³⁶ (N ^ε- decanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ²⁶ (N ^ε- octanoyl), A6c ³² , Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ²⁶ (N ^ε -tetradecanoyl), A6c ³² , Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ²⁶ (N ^ε- hexadecanoyl), A6c ³² , Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , A6c ³² , Lys ³⁴ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , A6c ³² , Lys ³⁴ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , A6c ³² , Lys ³⁴ (N ^ε- hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , A6c ³² , Lys ³⁴ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , A6c ³² , Lys ³⁴ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , A6c ³² , Lys ³⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , A6c ³² , Lys ³⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , A6c ³² , Lys ³⁶ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , A6c ³² , Lys ³⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , A6c ³² , Lys ³⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , A6c ³² , Lys ³⁶ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , A6c ³² , Lys ³⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , A6c ³² , Lys ³⁶ (N ^ε- decanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , A6c ³² , Lys ³⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , A6c ³² , Lys ³⁶ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.35 , Lys ²⁶ (N ^ε- octanoyl), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.35 , Lys ²⁶ (N ^ε -tetradecanoyl), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.35 , Lys ²⁶ (N ^ε- hexadecanoyl), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.35 , Arg ²⁶ , Lys ³⁴ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.35 , Arg ²⁶ , Lys ³⁴ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.35 , Arg ²⁶ , Lys ³⁴ (N ^ε- hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.35 , Arg ^26.34 , Lys ³⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.35 , Arg ^26.34 , Lys ³⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.35 , Arg ^26.34 , Lys ³⁶ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.35 , Glu ²³ , A6c ³² , Lys ³⁴ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , Lys ²⁶ (N ^ε- octanoyl), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , Lys ²⁶ (N ^ε -tetradecanoyl), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , Lys ²⁶ (N ^ε- hexadecanoyl), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , Lys ³⁴ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , A6c ³² , Lys ³⁴ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , Arg ²⁶ , Lys ³⁴ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , Arg ²⁶ , Lys ³⁴ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , Arg ²⁶ , Lys ³⁴ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , Lys ³⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , Lys ³⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , Lys ³⁶ (N ^ε -hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , Arg ^26.34 , Lys ³⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , Arg ^26.34 , Lys ³⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , Arg ^26.34 , Lys ³⁶ (N ^ε -hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.30.30 , Lys ²⁶ (N ^ε- octanoyl), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.30.30 , Lys ²⁶ (N ^ε -tetradecanoyl), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.30.30 , Lys ²⁶ (N ^ε- hexadecanoyl), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.30.30 , Arg ²⁶ , Lys ³⁴ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.30.30 , Arg ²⁶ , Lys ³⁴ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.30.35 , Arg ²⁶ , Lys ³⁴ (N ^ε- hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.30.35 , Arg ^26.34 , Lys ³⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.30.30 , Arg ^26.34 , Lys ³⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.30.35 , Arg ^26.34 , Lys ³⁶ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , A6c ³² , Lys ³⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , A6c ³² , Lys ³⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , A6c ³² , Lys ³⁶ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , Arg ^26.34 , A6c ³² , Lys ³⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , Arg ^26.34 , A6c ³² , Lys ³⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , Arg ^26.34 , A6c ³² , Lys ³⁶ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.35 , Glu ²³ , Arg ^26.34 , A6c ³² , Lys ³⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.35 , Glu ²³ , Arg ^26.34 , A6c ³² , Lys ³⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.35 , Glu ²³ , Arg ^26.34 , A6c ³² , Lys ³⁶ (N ^ε- hexadecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.30.305 , Glu ²³ , Arg ^26.34 , A6c ³² , Lys ³⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.30.305 , Glu ²³ , Arg ^26.34 , A6c ³² , Lys ³⁶ (N ^ε -tetradecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.30.305 , Glu ²³ , Arg ^26.34 , A6c ³² , Lys ³⁶ (N ^{ε ε-} hexadecanoyl)) hGLP-1 (7-36) NH ₂ , ((N ^α -HEPES-His) ⁷ , Aib ³⁵ ) hGLP-1 (7-36) NH ₂ , ((N ^α -HEPES-His) ⁷ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , ((N ^α -HEPES-His) ⁷ , Aib ⁸ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , ((N ^α -HEPA-His) ⁷ , Aib ³⁵ ) hGLP-1 (7-36) NH ₂ , ((N ^α -HEPA-His) ⁷ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , ((N ^α -HEPA-His) ⁷ , Aib ⁸ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , ((N ^α- tetradecanoyl-His) ⁷ , Aib ³⁵ ) hGLP-1 (7-36) NH ₂ , ((N ^α- tetradecanoyl-His) ⁷ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , ((N ^α- tetradecanoyl-His) ⁷ , Aib ^8.35 ) hGLP-1 (7-36) NH ₂ , ((N ^α- tetradecanoyl-His) ⁷ , Aib ⁸ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , ((N ^α- tetradecanoyl-His) ⁷ , Arg ^26.34 , Aib ³⁵ ) hGLP-1 (7-36) NH ₂ , ((N ^α- tetradecanoyl-His) ⁷ , Arg ^26.34 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , ((N ^α- tetradecanoyl-His) ⁷ , Aib ^8.35 , Arg ^26.34 ) hGLP-1 (7-36) NH ₂ , ((N ^α- tetradecanoyl-His) ⁷ , Aib ⁸ , Arg ^26.34 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , ((N ^α- tetradecanoyl-His) ⁷ , Arg ^26.26.34 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , ((N ^α- tetradecanoyl-His) ⁷ , Aib ^8.35 , Arg ^25.26.34 ) hGLP-1 (7-36) NH ₂ , ((N ^α- tetradecanoyl-His) ⁷ , Aib ⁸ , Arg ^25.26.34 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ²⁶ (N ^ε- octanesulfonyl), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ²⁶ (N ^ε- dodecansulfonyl), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ²⁶ (N ^ε- hexadecane sulfonyl), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , Lys ³⁴ (N ^ε- octanesulfonyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , Lys ³⁴ (N ^ε- dodecansulfonyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , Lys ³⁴ (N ^ε -hexadecane sulfonyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁶ (N ^ε- octanesulfonyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁶ (N ^ε- hexadecane sulfonyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Asp ²⁶ (1- (4-decylpiperazine)), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Asp ²⁶ (1- (4-dodecylpiperazine)), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Asp ²⁶ (1- (4-tetradecylpiperazine)), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Asp ²⁶ (1- (4-hexadecylpiperazine)), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , Asp ³⁴ (1- (4-decylpiperazine))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , Asp ³⁴ (1- (4-dodecylpiperazine))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , Asp ³⁴ (1- (4-tetradecylpiperazine)) hGLP-1 (7- 36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , Asp ³⁴ (1- (4-hexadecylpiperazine))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Asp ³⁶ (1- (4-decylpiperazine))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Asp ³⁶ (1- (4-dodecylpiperazine))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Asp ³⁶ (1- (4-hexadecylpiperazine))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Asp ³⁸ (1- (4-decylpiperazine))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Asp ³⁸ (1- (4-dodecylpiperazine))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Asp ³⁸ (1- (4-tetradecylpiperazine))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Asp ³⁸ (1- (4-hexadecylpiperazine))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^26.34 , Asp ³⁸ (1- (4-decylpiperazine))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^26.34 , Asp ³⁸ (1- (4-dodecylpiperazine))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^26.34 , Asp ³⁸ (1- (4-tetradecylpiperazine))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^26.34 , Asp ³⁸ (1- (4-hexadecylpiperazine))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^25.34 , Asp ²⁶ (1- (4-decylpiperazine))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.34 , Asp ²⁶ (1- (4-dodecylpiperazine))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.34 , Asp ²⁶ (1- (4-tetradecylpiperazine))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.34 , Asp ²⁶ (1- (4-hexadecylpiperazine))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26 , Asp ³⁴ (1- (4-decylpiperazine))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26 , Asp ³⁴ (1- (4-dodecylpiperazine))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26 , Asp ³⁴ (1- (4-tetradecylpiperazine))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26 , Asp ³⁴ (1- (4-hexadecylpiperazine))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26.34 , Asp ³⁶ (1- (4-decylpiperazine))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26.34 , Asp ³⁶ (1- (4-dodecylpiperazine))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26.34 , Asp ³⁶ (1- (4-tetradecylpiperazine))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26.34 , Asp ³⁶ (1- (4-hexadecylpiperazine))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26.34 , Asp ³⁸ (1- (4-decylpiperazine))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^25.26.34 , Asp ³⁸ (1- (4-dodecylpiperazine))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^25.26.34 , Asp ³⁸ (1- (4-tetradecylpiperazine))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^25.26.34 , Asp ³⁸ (1- (4-hexadecylpiperazine))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^25.26.34 , Asp ³⁸ (1- (4-decylpiperazine))) hGLP-1 (7-38) NH ₂ (Aib ^8.35.37 , Arg ^25.26.34 , Asp ³⁸ (1- (4-dodecylpiperazine))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^25.26.34 , Asp ³⁸ (1- (4-tetradecylpiperazine))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^25.26.34 , Asp ³⁸ (1- (4-hexadecylpiperazine))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Glu ³⁶ (1-dodecylamino)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²⁶ (1-dodecylamino), Arg ³⁴ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁸ , Glu ³⁴ (1-dodecylamino)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35.37 , Arg ^26.34 , Glu ³⁸ (1-dodecylamino)) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ³⁴ , Lys ²⁶ (N ^ε - (2- (4-decyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ³⁴ , Lys ²⁶ (N ^ε - (2- (4-dodecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ³⁴ , Lys ²⁶ (N ^ε - (2- (4-tetradecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ³⁴ , Lys ²⁶ (N ^ε - (2- (4-hexadecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , Lys ³⁴ (N ^ε - (2- (4-decyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , Lys ³⁴ (N ^ε - (2- (4-dodecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , Lys ³⁴ (N ^ε - (2- (4-tetradecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ²⁶ , Lys ³⁴ (N ^ε - (2- (4-hexadecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁶ (N ^ε - (2- (4-decyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁶ (N ^ε - (2- (4-dodecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁶ (N ^ε - (2- (4-hexadecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁸ (N ^ε - (2- (4-decyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁸ (N ^ε - (2- (4-dodecyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁸ (N ^ε - (2- (4-tetradecyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁸ (N ^ε - (2- (4-hexadecyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^26.34 , Lys ³⁸ (N ^ε - (2- (4-decyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^26.34 , Lys ³⁸ (N ^ε - (2- (4-dodecyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^26.34 , Lys ³⁸ (N ^ε - (2- (4-tetradecyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^26.34 , Lys ³⁸ (N ^ε - (2- (4-hexadecyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^25.34 , Lys ²⁶ (N ^ε - (2- (4-decyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.34 , Lys ²⁶ (N ^ε - (2- (4-dodecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.34 , Lys ²⁶ (N ^ε - (2- (4-tetradecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.34 , Lys ²⁶ (N ^ε - (2- (4-hexadecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26 , Lys ³⁴ (N ^ε - (2- (4-decyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26 , Lys ³⁴ (N ^ε - (2- (4-dodecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26 , Lys ³⁴ (N ^ε - (2- (4-tetradecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26 , Lys ³⁴ (N ^ε - (2- (4-hexadecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26.34 , Lys ³⁶ (N ^ε - (2- (4-decyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26.34 , Lys ³⁶ (N ^ε - (2- (4-dodecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26.34 , Lys ³⁶ (N ^ε - (2- (4-tetradecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26.34 , Lys ³⁶ (N ^ε - (2- (4-hexadecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^25.26.34 , Lys ³⁸ (N ^ε - (2- (4-decyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^25.26.34 , Lys ³⁸ (N ^ε - (2- (4-dodecyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^25.26.34 , Lys ³⁸ (N ^ε - (2- (4-tetradecyl-1-piperazine) - acetyl))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^25.26.34 , Lys ³⁸ (N ^ε - (2- (4-hexadecyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^25.26.34 , Lys ³⁸ (N ^ε - (2- (4-decyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^25.26.34 , Lys ³⁸ (N ^ε - (2- (4-dodecyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^25.26.34 , Lys ³⁸ (N ^ε - (2- (4-tetradecyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35.37 , Arg ^25.26.34 , Lys ³⁸ (N ^ε - (2- (4-hexadecyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁶ (N ^ε -decanoyl)) hGLP-1 (7-36) OH, (Aib ^8.35 , Lys ²⁵ , Arg ^26.34 , Lys ³⁶ (N ^ε- decanoyl)) hGLP-1 (7-36) OH, (Aib ^8.35 , Arg ^26.34 , Ava ³⁷ , Ado ³⁸ ) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Asp ³⁷ , Ava ³⁸ , Ado ³⁹ ) hGLP-1 (7-39) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Aun ³⁷ ) hGLP-1 (7-37) NH ₂ , (Aib ^8.17.35 ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ^26.34 , β-Ala ³⁵ , D-Asp ³⁷ , Ava ³⁸ , Aun ³⁹ ) hGLP-1 (7-39) NH ₂ , (Gly ⁸ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Ser ⁸ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Glu ^22.23 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Gly ⁸ , Aib ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ¹⁸ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Leu ²⁷ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ³³ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ¹⁸ , Leu ²⁷ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , D-Arg ³⁶ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , β-Ala ³⁵ , D-Arg ³⁷ ) hGLP-1 (7-37) NH ₂ , (Aib ^8.27 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.27 , β-Ala ^35.37 , Arg ³⁸ ) hGLP-1 (7-38) NH ₂ , (Aib ^8.27 , β-Ala ^35.37 , Arg ^38.39 ) hGLP-1 (7-39) NH ₂ , (Aib ⁸ , Lys ^18.27 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ²⁷ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , β-Ala ³⁵ , Arg ³⁸ ) hGLP-1 (7-38) NH ₂ , (Aib ⁸ , Arg ^26.34 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , D-Arg ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , β-Ala ³⁵ , Arg ³⁷ ) hGLP-1 (7-37) NH ₂ , (Aib ⁸ , Phe ³¹ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Phe ³¹ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Nal ³¹ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Nal ^28.31 ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Nal ³¹ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Phe ³¹ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Nal ^19.31 ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Nal ^12.31 ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ³⁶ (N ^ε- decanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ³⁴ , Lys ²⁶ (N ^ε- decanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁶ (N ^ε- dodecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , β-Ala ³⁵ , Ser ³⁷ (O-decanoyl)) hGLP-1 (7-37) NH ₂ , (Aib ^8.27 , β-Ala ^35.37 , Arg ³⁸ , Lys ³⁹ (N ^ε- octanoyl)) hGLP-1 (7-39) NH ₂ , (Aib ⁸ , Arg ^26.34 , β-Ala ³⁵ , Lys ³⁷ (N ^{ε ε-} octanoyl)) hGLP-1 (7-37) NH ₂ , (Aib ⁸ , Arg ^26.34 , β-Ala ³⁵ , Lys ³⁷ (N ^ε- decanoyl)) hGLP-1 (7-37) NH ₂ , (Aib ⁸ , Arg ^26.34 , β-Ala ³⁵ , Lys ³⁷ (N ^ε -tetradecanoyl)) hGLP-1 (7-37) NH ₂ , (Aib ⁸ , Arg ^26.34 , β-Ala ³⁵ , Lys ³⁷ (N ^{ε ε-} dodecanoyl)) hGLP-1 (7-37) NH ₂ , (Aib ⁸ , Arg ^26.34 , β-Ala ³⁵ , Lys ³⁷ (N ^{ε ε-} dodecanoyl)) hGLP-1 (8-37) NH ₂ , or a pharmaceutically acceptable salt thereof. 16. The compound of claim 15, wherein said compound is (Aib ^8.35 , A6c ³² ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.24.35 ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , A6c ³² ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Glu ²³ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁶ (N ^ε- octanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁶ (N ^ε -decanoyl)) hGLP-1 (7-36) OH, (Aib ^8.35 , Lys ²⁵ , Arg ^26.34 , Lys ³⁶ (N ^ε- decanoyl)) hGLP-1 (7-36) OH, (Aib ^8.35 , Arg ^26.34 , β-Ala ³⁵ , Lys ³⁶ (N ^ε -Ac-decanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Ava ³⁷ , Ado ³⁸ ) hGLP-1 (7-38) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Asp ³⁷ , Ava ³⁸ , Ado ³⁹ ) hGLP-1 (7-39) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Aun ³⁷ ) hGLP-1 (7-37) NH ₂ , (Aib ^8.17.35 ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Arg ^26.34 , β-Ala ³⁵ , D-Asp ³⁷ , Ava ³⁸ , Aun ³⁹ ) hGLP-1 (7-39) NH ₂ , (Gly ⁸ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Ser ⁸ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Glu ^22.23 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Gly ⁸ , Aib ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ¹⁸ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Leu ²⁷ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ³³ , β-Ala ³⁵⁾ hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ¹⁸ , Leu ²⁷ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , D-Arg ³⁶ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , β-Ala ³⁵ , D-Arg ³⁷ ) hGLP-1 (7-37) NH ₂ , (Aib ^8.27 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.27 , β-Ala ^35.37 , Arg ³⁸ ) hGLP-1 (7-38) NH ₂ , (Aib ^8.27 , β-Ala ^35.37 , Arg ^38.39 ) hGLP-1 (7-39) NH ₂ , (Aib ⁸ , Lys ^18.27 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , Lys ²⁷ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , β-Ala ³⁵ , Arg ³⁸ ) hGLP-1 (7-38) NH ₂ , (Aib ⁸ , Arg ^26.34 , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , D-Arg ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , β-Ala ³⁵ , Arg ³⁷ ) hGLP-1 (7-37) NH ₂ , (Aib ⁸ , Phe ³¹ , β-Ala ³⁵ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Phe ³¹ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Nal ³¹ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Nal ^28.31 ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Nal ³¹ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Phe ³¹ ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Nal ^19.31 ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Nal ^13.31 ) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Lys ³⁶ (N ^ε- decanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ³⁴ , Lys ²⁶ (N ^ε- decanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ^8.35 , Arg ^26.34 , Lys ³⁶ (N ^ε- dodecanoyl)) hGLP-1 (7-36) NH ₂ , (Aib ⁸ , β-Ala ³⁵ , Ser ³⁷ (O-decanoyl)) hGLP-1 (7-37) NH ₂ , (Aib ^8.27 , β-Ala ^35.37 , Arg ³⁸ , Lys ³⁹ (N ^ε- octanoyl)) hGLP-1 (7-39) NH ₂ , (Aib ⁸ , Arg ^26.34 , β-Ala ³⁵ , Lys ³⁷ (N ^{ε ε-} octanoyl)) hGLP-1 (7-37) NH ₂ , (Aib ⁸ , Arg ^26.34 , β-Ala ³⁵ , Lys ³⁷ (N ^ε- decanoyl)) hGLP-1 (7-37) NH ₂ , (Aib ⁸ , Arg ^26.34 , β-Ala ³⁵ , Lys ³⁷ (N ^ε -tetradecanoyl)) hGLP-1 (7-37) NH ₂ , or a pharmaceutically acceptable salt thereof. 17. The compound according to any one of claims 1 to 10 or 15, or 16, as an active ingredient of a medicament for treating a disease. 18. The compound of claim 17, wherein the disease is selected from the group consisting of type I diabetes, type II diabetes, obesity, glucagonoma, secretory disorders of the respiratory tract, metabolic disorders, arthritis, osteoporosis, diseases of the central nervous system, restenosis and neurodegenerative diseases.